PMV Pharmaceuticals CEO David Mack's 2022 pay rises 1% to $3.6M
PMV Pharmaceuticals reports 2022 executive compensation
By ExecPay News
Published: April 28, 2023
PMV Pharmaceuticals reported fiscal year 2022 executive compensation information on April 28, 2023.
In 2022, three executives at PMV Pharmaceuticals received on average a compensation package of $2.6M, a 19% increase compared to previous year.
Average pay of disclosed executives at PMV Pharmaceuticals
David H. Mack, Chief Executive Officer, received $3.6M in total, which increased by 1% compared to 2021. 79% of Mack's compensation, or $2.8M, was in option awards. Mack also received $198K in non-equity incentive plan and $564K in salary.
Leila Alland, Chief Medical Officer, received a compensation package of $2.5M, which increased by 78% compared to previous year. 47% of the compensation package, or $1.2M, was in option awards.
Winston Kung, Chief Financial Officer, earned $1.8M in 2022, a 6% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 28, 2023.